• Lenacapavir led to virologic suppression in 81% of patients with HIV

    10 days ago - By Healio

    Subcutaneous lenacapavir in combination with an optimized background regimen led to sustained virologic suppression in 81% of heavily treated people with HIV at week 26, data from an ongoing phase 2/3 study showed.
    Lenacapavir, for which Gilead Sciences submitted a new drug application to the FDA, is an investigational, long-acting HIV-1 capsid inhibitor that is given subcutaneously every 6 months.
    Jean-Michel Molina, MD, the head of the infectious disease department at the Saint-Louis Hospital and Lariboisière Hospital in Paris, France, and colleagues presented the phase 2/3 data at the
    Read more ...

     

  • Toward one drug to treat all coronaviruses

    Toward one drug to treat all coronaviruses

    10 days ago - By ScienceDaily

    Researchers have analyzed viral proteins across 27 coronavirus species and thousands of samples from COVID-19 patients, identifying highly conserved sequences that could make the best drug targets.
    Read more ...

     

  • Novel Drug Helped HIV Patients Achieve Viral Suppression

    Novel Drug Helped HIV Patients Achieve Viral Suppression

    10 days ago - By MedPageToday

    More than 80% of heavily treatment-experienced HIV patients with multi-drug resistance who received long-acting subcutaneous lenacapavir along with an optimized background regimen experienced viral suppression at week 26, according...
    Read more ...